X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 2 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding X4 Pharmaceuticals, Inc changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 59 | 96 | +37 |
| Shares | 61.5M | 112.9M | +51.5M (+83.7%) |
| Value | $53.6M | $219.1M | +$165.5M (+308.6%) |
New holders (45)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (8)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Cormorant Asset Management, LP | 1,628,980 | $1.42M |
| Ghost Tree Capital, LLC | 850,000 | $740.0K |
| Scoggin Management LP | 484,796 | $567.0K |
| XTX Topco Ltd | 96,649 | $84.1K |
| Landscape Capital Management, L.L.C. | 42,252 | $36.8K |
| Renaissance Technologies LLC | 10,092 | $9.00K |
| Advisor Group Holdings, Inc. | 529 | $460 |
| CWM, LLC | 2 | $0 |